Nothing Special   »   [go: up one dir, main page]

HK1210434A1 - Pharmaceutical formulation containing thienotriazolodiazepine compounds - Google Patents

Pharmaceutical formulation containing thienotriazolodiazepine compounds

Info

Publication number
HK1210434A1
HK1210434A1 HK15111309.6A HK15111309A HK1210434A1 HK 1210434 A1 HK1210434 A1 HK 1210434A1 HK 15111309 A HK15111309 A HK 15111309A HK 1210434 A1 HK1210434 A1 HK 1210434A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
formulation containing
thienotriazolodiazepine compounds
containing thienotriazolodiazepine
compounds
Prior art date
Application number
HK15111309.6A
Other languages
English (en)
Chinese (zh)
Inventor
杰夫.高奇
瑞安.米尼克斯
Original Assignee
Oncoethix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Gmbh filed Critical Oncoethix Gmbh
Publication of HK1210434A1 publication Critical patent/HK1210434A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
HK15111309.6A 2012-09-28 2015-11-17 Pharmaceutical formulation containing thienotriazolodiazepine compounds HK1210434A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261707465P 2012-09-28 2012-09-28
US201361782882P 2013-03-14 2013-03-14
US201361831811P 2013-06-06 2013-06-06
PCT/IB2013/003026 WO2014068402A2 (fr) 2012-09-28 2013-09-27 Formulation pharmaceutique contenant des composés thienotriazolodiazepine

Publications (1)

Publication Number Publication Date
HK1210434A1 true HK1210434A1 (en) 2016-04-22

Family

ID=50475880

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111309.6A HK1210434A1 (en) 2012-09-28 2015-11-17 Pharmaceutical formulation containing thienotriazolodiazepine compounds
HK15112002.4A HK1211209A1 (en) 2012-09-28 2015-12-04 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15112002.4A HK1211209A1 (en) 2012-09-28 2015-12-04 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Country Status (13)

Country Link
US (1) US20140107107A1 (fr)
EP (1) EP2900221B1 (fr)
JP (1) JP2015531365A (fr)
KR (1) KR20150100613A (fr)
CN (1) CN104968334B (fr)
AU (1) AU2013340483B2 (fr)
BR (1) BR112015006537A2 (fr)
CA (1) CA2885944A1 (fr)
HK (2) HK1210434A1 (fr)
IN (1) IN2015DN03135A (fr)
MX (1) MX2015003771A (fr)
RU (1) RU2015115634A (fr)
WO (1) WO2014068402A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252808B2 (en) 2010-05-14 2015-05-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
WO2011143660A2 (fr) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions et méthodes de traitement de la leucémie
US9266891B2 (en) * 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Betタンパク質阻害剤としての三環式複素環
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
WO2015014998A1 (fr) * 2013-08-01 2015-02-05 Oncoethix Sa Préparation pharmaceutique contenant des composés de thiénotriazolodiazépine
WO2015018520A1 (fr) * 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur bet-brd représentant un nouvel agent pour un lymphome anaplasique à grandes cellules alk positif
EP3030242A1 (fr) * 2013-08-06 2016-06-15 Oncoethix GmbH Procédé de traitement de lymphome diffus à grande cellules b (ldgcb) au moyen d'un inhibiteur de bromodomaine de bet
WO2015018523A1 (fr) * 2013-08-06 2015-02-12 Oncoethix Sa Nouvel inhibiteur de bet-brd pour le traitement de tumeurs solides
WO2015018522A1 (fr) * 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
WO2015081189A1 (fr) 2013-11-26 2015-06-04 Incyte Corporation Hétérocycles bicycliques servant d'inhibiteurs des protéines bet
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
KR20160079823A (ko) * 2013-11-27 2016-07-06 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법
WO2015095492A1 (fr) 2013-12-19 2015-06-25 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs des protéines bet
EP3099693A4 (fr) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Utilisations des dérivés de diazépane
JP2017504653A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアミノピリミジンベンゼンスルホン誘導体およびその使用
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
ES2784846T3 (es) 2014-04-23 2020-10-01 Incyte Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
CA2947593A1 (fr) * 2014-05-02 2015-11-05 Oncoethix Gmbh Methode de traitement de lymphome non hodgkinien resistant, de medulloblastome et/ou de cancer bronchopulmonaire non a petites cellules alk+ a l'aide de composes de thienotriazolodiazepine
WO2015168587A1 (fr) * 2014-05-02 2015-11-05 Oncoethix Sa Procédé de traitement de myélome multiple résistant et de lymphome des cellules du manteau à l'aide de composés de thiénotriazolodiazépine
RU2016146099A (ru) * 2014-05-02 2018-06-05 Онкоэтикс Гмбх Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений
WO2015169953A1 (fr) * 2014-05-08 2015-11-12 Oncoethix Gmbh Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine
CA2947970A1 (fr) * 2014-05-08 2015-11-12 Oncoethix Gmbh Methode de traitement du cancer du sein triple negatif a l'aide de composes de thienotriazolodiazepine
MX2016016388A (es) 2014-06-13 2017-04-06 Oncoethix Gmbh Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
CN107427524A (zh) * 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
EP3194406B8 (fr) 2014-09-15 2021-03-31 Incyte Corporation Composes triheterocycliques a utilisation comme inhibiteurs de proteine bet
UA122130C2 (uk) * 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
WO2016176335A1 (fr) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Otx-015 deutéré
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
SG10202007090UA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Cyano thienotriazolodiazepines and uses thereof
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
BR112018009798A8 (pt) 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
WO2017106492A1 (fr) 2015-12-18 2017-06-22 Ignyta, Inc. Combinaisons pour le traitement du cancer
EP3192502A1 (fr) * 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag
WO2017121806A1 (fr) * 2016-01-15 2017-07-20 Sandoz Ag Composition pharmaceutique de selexipag
PE20240236A1 (es) 2016-06-20 2024-02-16 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
CA3069339A1 (fr) 2017-07-19 2019-01-24 Ignyta, Inc. Compositions pharmaceutiques contenant de l'entrectinib
JP7311498B2 (ja) * 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
WO2019145410A1 (fr) 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Traitement combiné de leucémie myéloïde aiguë
MX2022003150A (es) * 2019-09-18 2022-04-06 Bristol Myers Squibb Co Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022034914A1 (fr) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 Préparation pharmaceutique solide facilement soluble et son procédé de production
CN116098870B (zh) * 2023-04-10 2023-07-25 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的固体分散体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0989131T3 (da) * 1996-09-13 2003-03-03 Mitsubishi Pharma Corp Thienotriazolodiazepinforbindelser og deres medicinske anvendelse
CA2412776C (fr) * 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
CA2828610A1 (fr) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Formulations de dispersions solides et leurs procedes d'utilisation

Also Published As

Publication number Publication date
AU2013340483B2 (en) 2018-01-18
JP2015531365A (ja) 2015-11-02
IN2015DN03135A (fr) 2015-10-02
CA2885944A1 (fr) 2014-05-08
CN104968334B (zh) 2018-09-14
KR20150100613A (ko) 2015-09-02
US20140107107A1 (en) 2014-04-17
EP2900221B1 (fr) 2019-03-06
BR112015006537A2 (pt) 2017-07-04
HK1211209A1 (en) 2016-05-20
WO2014068402A2 (fr) 2014-05-08
EP2900221A2 (fr) 2015-08-05
MX2015003771A (es) 2016-03-04
WO2014068402A3 (fr) 2014-10-16
CN104968334A (zh) 2015-10-07
RU2015115634A (ru) 2016-11-20
AU2013340483A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
HK1211209A1 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
ZA201501930B (en) Pharmaceutical composition
HK1203812A1 (en) Novel pharmaceutical formulations
EP2931285A4 (fr) Compositions pharmaceutiques
EP2832730A4 (fr) Composition pharmaceutique contenant du mirabegron
HK1205146A1 (en) Pharmaceutical formulation
GB201205164D0 (en) Pharmaceutical compounds
HK1205683A1 (en) Pharmaceutical formulation having improved stability
HK1216619A1 (zh) 藥物化合物
ZA201502987B (en) Pharmaceutical composition
LT2638894T (lt) Farmacinė kompozicija, turinti fosfolipido
RS59631B1 (sr) Farmaceutska formulacija koja sadrži kurkumin
EP2897590A4 (fr) Composition pharmaceutique
EP2883546A4 (fr) Nouvelle composition pharmaceutique à libération différentielle contenant trois principes actifs
GB201202027D0 (en) Pharmaceutical compounds
SG11201406097SA (en) Capsule formulation
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
HK1209339A1 (en) Pharmaceutical formulations
EP2851078A4 (fr) Composition pharmaceutique
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201203253D0 (en) Pharmaceutical compounds
ZA201400751B (en) Pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations